Jan. 15, 2014 — A novel study
determined that monitoring inactive chronic hepatitis B (HBV) carriers
is a cost-effective strategy for China. However, results published in
Hepatology,
a journal of the American Association for the Study of Liver Diseases,
show that increasing treatment, monitoring and adherence to therapy are
necessary to achieve significant health benefits at the population
level.